Publications by Kristen Lorentz

Human Kunitz-type protease inhibitor engineered for enhanced matrix retention extends longevity of fibrin biomaterials

Jeffrey Alan Hubbell, Peter Frey, Kristen Lorentz, Priscilla Suhasna Maithili Briquez, Hans Mattias Larsson

Aprotinin is a broad-spectrum serine protease inhibitor used in the clinic as an anti-fibrinolytic agent in fibrin-based tissue sealants. However, upon re-exposure, some patients suffer from hypersensitivity immune reactions likely related to the bovine or ...

2017

Long-lasting fibrin matrices ensure stable and functional angiogenesis by highly tunable, sustained delivery of recombinant VEGF(164)

Mikaël Martino, Jeffrey Alan Hubbell, Kristen Lorentz, Elena Groppa, Martin Ehrbar, Veronica Sacchi

Clinical trials of therapeutic angiogenesis by vascular endothelial growth factor (VEGF) gene delivery failed to show efficacy. Major challenges include the need to precisely control in vivo distribution of growth factor dose and duration of expression. Re ...

National Academy of Sciences2014

Materials and protein engineering approaches for modulating immunity

Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Marie Ballester, Stephane Kontos, Kristen Lorentz, Alizée Jéléna Grimm, Laura Jeanbart, David Scott Wilson, Kym Lorenz Brünggel

Amer Chemical Soc2014

Engineered insulin-like growth factor-1 for improved smooth muscle regeneration

Lirong Yang, Jeffrey Alan Hubbell, Peter Frey, Kristen Lorentz

Insulin-like growth factor-1 (IGF-1) has been shown to induce potent mitogenic responses in various cell types, yet its sustained local delivery is still an underdeveloped domain in the clinic. We report here an engineered IGF-1 that facilitates extended l ...

2012

Longterm cell-demanded release of TG-VEGF for the development of mature vascular networks in vivo

Jeffrey Alan Hubbell, Daniel Eberli, Kristen Lorentz, Martin Ehrbar

Wiley-Blackwell2012

Biofunctional Scaffold Design for Soft Tissue Regeneration

Kristen Lorentz

Fibrin has long been used clinically for hemostasis and sealing and has been extensively characterized as a biomaterial. Yet, in terms of harnessing its potential for use in tissue regeneration, there remains a wide gap between in vitro experimentation and ...

EPFL2011

Tg-aprotinin fusion proteins and matrices thereof

Jeffrey Alan Hubbell, Peter Frey, Kristen Lorentz

Fusion proteins containing a first domain and a second domain, where the first domain contains a crosslinkable substrate domain and the second domain contains a fibrinolysis inhibitor, are provided. In a preferred embodiment, the fibrinolysis inhibitor is ...

2011

Engineered aprotinin for improved stability of fibrin biomaterials

Jeffrey Alan Hubbell, Peter Frey, Stephane Kontos, Kristen Lorentz

Fibrin has been long used clinically for hemostasis and sealing, yet extension of use in other applications has been limited due to its relatively rapid resorption in vivo, even with addition of aprotinin or other protease inhibitors. We report an engineer ...

2011

Expression and purification of recombinant aprotinin for enhanced stability of fibrin biomaterials

Jeffrey Alan Hubbell, Peter Frey, Kristen Lorentz

2008